Follow The Filings

CHE Chemed Corporation

Health Care, filed as CHEMED CORP NEW (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by CHE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CHE insider trades
  • None no insider bought on the open market
  • $8.8M sold by 5 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Kevin J McNamara CEO
    Sale
    $1M 2,000 shares at $513.45 2.9% of stake
    Traded Sep 28 Filed Sep 30
  2. Kevin J McNamara CEO
    Sale
    $1M 2,000 shares at $501.40 2.8% of stake
    Traded Sep 18 Filed Sep 21
  3. Spencer S Lee executive vice president
    Sale
    $541K 1,000 shares at $541.04 6.7% of stake
    Traded Aug 21 Filed Aug 24
  4. Kevin J McNamara CEO
    Sale
    $1.1M 2,000 shares at $541.16 2.8% of stake
    Traded Aug 21 Filed Aug 24
  5. Kevin J McNamara CEO
    Sale
    $1.1M 2,000 shares at $539.51 2.8% of stake
    Traded Aug 3 Filed Aug 4
  6. Patrick P Grace Director
    Sale
    $101K 190 shares at $532.00 5.1% of stake
    Traded Jul 31 Filed Aug 3
  7. Andrea R Lindell Director
    Sale
    $603K 1,347 shares at $447.33 23% of stake
    Traded Jun 9 Filed Jun 10
  8. George J Walsh III Director
    Sale
    $219K 500 shares at $437.83 14% of stake
    Traded May 29 Filed May 29
  9. Patrick P Grace Director
    Sale
    $26K 60 shares at $425.78 1.8% of stake
    Traded May 8 Filed May 8
  10. Kevin J McNamara CEO
    Sale
    $842K 2,000 shares at $421.13 2.2% of stake
    Traded May 1 Filed May 4
  11. Kevin J McNamara CEO
    Sale
    $554K 1,500 shares at $369.37 1.6% of stake
    Traded Mar 27 Filed Mar 30
  12. Kevin J McNamara CEO
    Sale
    $806K 2,000 shares at $403.18 2.1% of stake
    Traded Mar 12 Filed Mar 13
  13. Kevin J McNamara CEO
    Sale
    $875K 2,000 shares at $437.55 2.1% of stake
    Traded Nov 24, 2025 Filed Nov 25, 2025

Also filed in the last 12 months, not counted as buying or selling: 17 option exercises, 11 share withholdings for taxes, 7 stock grants, and 2 gifts.

Congress

2 members of Congress traded CHE in the last three years: 1 buy and 2 sales. 1 member listed it in 2025 annual reports.

All Congress trades
  1. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Jun 24, 2025 filed Aug 13, 2025
  2. Byron Donalds R-FL-19 Sell $1K–$15K Mar 6, 2025 filed Apr 14, 2025
  3. Byron Donalds R-FL-19Spouse Sell $1K–$15K Mar 6, 2025 filed Apr 14, 2025

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
10-Q
8-K 2.02,9.01
SCHEDULE 13G —
10-Q
8-K 2.02,9.01
8-K 5.07
SCHEDULE 13G —
SCHEDULE 13G —
10-Q
8-K 2.02,9.01
8-K 1.01,2.03,9.01
DEF 14A

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.32B $1.53B —
Net income $272.51M $302M $265.24M
Net margin * 20.7% 19.7% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $500.84M $394.75M $302.62M
Total non-current assets * $1.17B $1.27B $1.24B
Total assets $1.67B $1.67B $1.54B
Total current liabilities $312.05M $285.7M $287.13M
Total non-current liabilities * $248.17M $263.89M $271.65M
Total equity $1.11B $1.12B $0.979B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $330.3M $417.5M $388.27M
Cash from investing -$60.64M -$143.91M -$59.34M
Cash from financing -$79.82M -$359.19M -$432.77M
Net change in cash * $189.83M -$85.61M -$103.84M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.